Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 7284 - 7285
Main Authors Abdallah, Al-Ola, Cowan, Andrew J, Leleu, Xavier, Touzeau, Cyrille, Lipe, Brea, Medvedova, Eva, Costello, Caitlin, Hillengass, Jens, Bergsagel, P. Leif, Mawad, Raya, Schade, Henning, Morillo Giles, Daniel, Oriol, Albert, Yaron, Yifah, Ng, Patrick P, Madan, Sumit
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-159665